Are you Dr. Lightfoot?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 39 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
3319 Spring St
Davenport, IA 52807Phone+1 563-359-1641Fax+1 563-359-4634
Summary
- Dr. Andrew Lightfoot, MD is a general surgeon in Davenport, Iowa. He is currently licensed to practice medicine in Iowa, Illinois, and Pennsylvania. He is affiliated with Genesis Medical Center - Davenport.
Education & Training
- University of Iowa Hospitals and ClinicsResidency, Urology, 2007 - 2013
- University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 2007
Certifications & Licensure
- IA State Medical License 2007 - 2026
- IL State Medical License 2014 - 2026
- PA State Medical License 2013 - 2014
- American Board of Urology Urology
Publications & Presentations
PubMed
- 62 citationsUtility of the RENAL nephrometry scoring system in the real world: predicting surgeon operative preference and complication risk.Henry M. Rosevear, Paul Gellhaus, Andrew J. Lightfoot, Timothy P. Kresowik, Fadi N. Joudi
BJU International. 2012-03-01 - 88 citationsBacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatme...Kenneth G. Nepple, Andrew J. Lightfoot, Henry M. Rosevear, Michael A. O’Donnell, Donald L. Lamm
The Journal of Urology. 2010-11-01 - 14 citationsCurrent and Future Need for Academic Urologists in the United StatesAndrew J. Lightfoot, Henry M. Rosevear, William D. Steers, Chad R. Tracy
The Journal of Urology. 2011-06-01
Press Mentions
- Procarta Receives CARB-X Award of up to $9.2 MillionSeptember 17th, 2019
- Procarta Raises €1.5 Million to Develop a New Class of Antibiotics to Combat Antimicrobial ResistanceMarch 5th, 2019
- EU Referendum: Now Top Life Science Bosses Warn of Brexit Risk, Including GSK, AstraZeneca and Pfizer in Open LaterMay 8th, 2016